Decades of efforts in engineering in vitro cancer models have advanced drug discovery and
the insight into cancer biology. However, the establishment of preclinical models that enable …

Over the past 15 years, the field of oncology research has witnessed significant progress in
the development of new cell culture models, such as tumor-on-chip (ToC) systems. In this …

SUMMARY Glioblastoma, isocitrate dehydrogenase (IDH)-wildtype (hereafter, GB), is an
aggressive brain malignancy associated with a dismal prognosis and poor quality of life …

In vitro models of the human blood–brain barrier (BBB) are increasingly used to develop
therapeutics that can cross the BBB for treating diseases of the central nervous system. Here …

Cancer thrives in a complex environment where interactions between cellular and acellular
components, surrounding the tumor, play a crucial role in disease development and …

Interactions between immunocytes and Neural Stem Cells (NSCs) in glioblastoma
multiforme still remains unclear. Here, microglial cells and NSCs in peri-tumoral tissue were …

Glioblastoma is the most common malignant primary central nervous system tumor and one
of the most debilitating cancers. The prognosis of patients with glioblastoma remains poor …

The coordinated migration of invasive tumor cells is a complex and dynamic mechanism
driven by diverse cellular and molecular events. Unfortunately, the inherent heterogeneity …

Tumor tissue engineering holds great promise for replicating the physiological and
behavioral characteristics of tumors in vitro. Advances in this field have led to new …

Glioblastoma is an aggressive brain tumor with an average life expectancy between 14 and
16 months after diagnosis. The Ki-67 labeling index (LI), a measure of cellular proliferation …